Thu, May 10, 2018
Wed, May 9, 2018
Tue, May 8, 2018
Mon, May 7, 2018
Fri, May 4, 2018
Thu, May 3, 2018
Wed, May 2, 2018
Tue, May 1, 2018
Mon, April 30, 2018
Fri, April 27, 2018

Matthew Luchini Maintained (BLUE) at Buy with Decreased Target to $216 on, May 3rd, 2018


//stocks-investing.news-articles.net/content/201 .. ith-decreased-target-to-216-on-may-3rd-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Matthew Luchini of BMO Capital, Maintained "bluebird bio, Inc." (BLUE) at Buy with Decreased Target from $222 to $216 on, May 3rd, 2018.

Matthew has made no other calls on BLUE in the last 4 months.



There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, all agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $209 on, Wednesday, March 21st, 2018
  • Ying Huang of "B of A Securities" Maintained at Hold with Increased Target to $218 on, Thursday, February 22nd, 2018
  • Michael Schmidt of "Leerink Swann" Downgraded from Buy to Hold on, Thursday, January 25th, 2018

Publication Contributing Sources